Form 4: Herman Sanchez Receives Stock Options in Harvard Apparatus Regenerative Technology, Inc.
SEC Form 4 Filing
Director Herman Sanchez receives stock options as part of annual equity grant and in lieu of cash compensation from Harvard Apparatus Regenerative Technology, Inc.
Summary
- Herman Sanchez, a director at Harvard Apparatus Regenerative Technology, Inc. (HRGN), received stock options on June 27, 2024.
- He received 10,204 stock options as an annual equity grant, vesting in four equal installments on September 27, 2024, December 27, 2024, March 27, 2025, and June 27, 2025.
- Additionally, Sanchez received 8,215 stock options in lieu of cash compensation, vesting in four equal installments on June 27, 2024, June 30, 2024, September 30, 2024, and December 31, 2024.
- The exercise price for both stock option grants is $2.92 per share, and they expire on June 27, 2034.
Sentiment
Score: 6
Explanation: The document is a routine disclosure of stock option grants, which is neutral to slightly positive as it aligns director interests with shareholders.
Positives
- The grant of stock options to a director aligns their interests with those of the shareholders.
- The vesting schedule encourages continued service and contribution to the company.
Industry Context
Stock option grants are a common form of compensation for directors, especially in smaller companies, to align their interests with shareholders and conserve cash.
Comparison to Industry Standards
- Director compensation packages vary widely across the biotechnology and medical device industries.
- Stock options are a typical component, but the size and vesting schedules depend on company size, performance, and individual contributions.
- Comparing HRGN's director compensation to similar-sized companies in the regenerative medicine space would provide a more detailed benchmark.
Stakeholder Impact
- Shareholders may view the stock option grants positively as they incentivize directors to increase shareholder value.
- The grants have a dilutive effect on existing shareholders, although the impact is likely minimal given the size of the grants.
Key Dates
| Date | Description |
|---|---|
| 06/27/2024 | Date of stock option grants and first vesting date for options in lieu of cash compensation. |
| 06/30/2024 | Second vesting date for options granted in lieu of cash compensation. |
| 07/15/2024 | Date of Form 4 filing. |
| 09/27/2024 | First vesting date for annual equity grant options. |
| 09/30/2024 | Third vesting date for options granted in lieu of cash compensation. |
| 12/27/2024 | Second vesting date for annual equity grant options. |
| 12/31/2024 | Final vesting date for options granted in lieu of cash compensation. |
| 03/27/2025 | Third vesting date for annual equity grant options. |
| 06/27/2025 | Final vesting date for annual equity grant options. |
| 06/27/2034 | Expiration date for all stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.